Maybe Logo Early Access

Tools / Inside Trading Tracker

Inside Trading Tracker

Track insider trading activity at publicly traded companies to understand how executives are trading their shares.

    Gilead Sciences, Inc. (GILD) Insider Trading Activity

    Healthcare • Drug Manufacturers - General • 18,000 employees

    Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.

    Total Value

    -$26,642,162.11

    Total Shares

    3,317,530

    Average Trade Value

    -$409,879.42

    Most Active Insider

    Dickinson Andrew D

    Total Activity: $93,024,314

    Largest Single Transaction

    $14,999,996

    by Gilead Sciences, Inc. on Feb 18, 2025

    30-Day Activity

    0 Transactions

    Volume: 0 shares
    Value: $0

    Name
    Position
    Date
    Shares
    Value
    Holdings
    Type
    10% Owner
    Feb 18, 2025 1,363,636 $14,999,996 31,424,760 (+4.3%) Purchase
    Chief Financial Officer
    Officer
    Feb 18, 2025 2,500 $260,225 169,061 (-1.5%) Sale
    Chief Financial Officer
    Officer
    Feb 12, 2025 18,210 $1,520,353 308,899 (+5.9%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Feb 12, 2025 137,676 $14,073,241 171,223 (-80.4%) Sale
    Chief Financial Officer
    Officer
    Feb 12, 2025 15,600 $1,259,232 290,689 (+5.4%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Feb 12, 2025 77,691 $4,965,232 248,914 (+31.2%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Feb 12, 2025 26,175 $1,516,056 275,089 (+9.5%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Feb 4, 2025 12,371 $0 34,011 (+36.4%) Grant
    Chief Commercial Officer
    Officer
    Feb 4, 2025 19,793 $10,000 94,933 (+20.8%) Grant
    Chief Commercial Officer
    Officer
    Feb 4, 2025 45,666 $4,474,811 119,979 (-38.1%) Payment of Exercise Price
    Chief Commercial Officer
    Officer
    Feb 4, 2025 70,712 $10,000 165,645 (+42.7%) Grant
    Chairman CEO
    Director, Officer
    Feb 4, 2025 164,473 $10,000 726,032 (+22.7%) Grant
    Chairman CEO
    Director, Officer
    Feb 4, 2025 60,031 $10,000 561,559 (+10.7%) Grant
    Chairman CEO
    Director, Officer
    Feb 4, 2025 108,156 $10,598,206 617,876 (-17.5%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Feb 4, 2025 43,138 $4,227,093 171,223 (-25.2%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Feb 4, 2025 709 $10,000 37,787 (+1.9%) Grant
    Chief Financial Officer
    Officer
    Feb 4, 2025 64,695 $10,000 214,361 (+30.2%) Grant
    Chief Financial Officer
    Officer
    Feb 4, 2025 19,793 $10,000 149,666 (+13.2%) Grant
    Chief Financial Officer
    Officer
    Jan 31, 2025 71,850 $5,197,629 227,893 (+31.5%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Jan 31, 2025 26,170 $1,515,766 156,043 (+16.8%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Jan 31, 2025 142,180 $13,822,740 129,873 (-109.5%) Sale
    Chief Financial Officer
    Officer
    Jan 31, 2025 44,160 $2,887,181 273,053 (+16.2%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Jan 25, 2025 515 $0 21,827 (+2.4%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Jan 25, 2025 187 $17,404 21,640 (-0.9%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Jan 15, 2025 2,500 $228,375 129,873 (-1.9%) Sale
    10% Owner
    Dec 18, 2024 1,759,978 $1,830,377 9,105,451 (+19.3%) Purchase
    Chief Financial Officer
    Officer
    Dec 16, 2024 8,500 $781,660 132,373 (-6.4%) Sale
    Svp, Controllership
    Officer
    Dec 13, 2024 157 $14,421 37,078 (-0.4%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Dec 13, 2024 157 $10,000 37,533 (+0.4%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Dec 10, 2024 639 $0 21,618 (+3.0%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Dec 10, 2024 3,820 $0 84,621 (+4.5%) Exercise/Conversion
    Chief Commercial Officer
    Officer
    Dec 10, 2024 3,752 $0 76,879 (+4.9%) Exercise/Conversion
    Chairman CEO
    Director, Officer
    Dec 10, 2024 4,762 $439,723 501,528 (-0.9%) Payment of Exercise Price
    Chief Medical Officer
    Officer
    Dec 10, 2024 1,771 $163,534 82,850 (-2.1%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Dec 10, 2024 408 $37,675 37,078 (-1.1%) Payment of Exercise Price
    Chief Commercial Officer
    Officer
    Dec 10, 2024 1,739 $160,579 75,140 (-2.3%) Payment of Exercise Price
    Svp, Controllership
    Officer
    Dec 10, 2024 901 $0 37,486 (+2.4%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Dec 10, 2024 306 $28,256 21,312 (-1.4%) Payment of Exercise Price
    Chairman CEO
    Director, Officer
    Dec 10, 2024 10,295 $0 506,290 (+2.0%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Dec 10, 2024 3,640 $0 142,559 (+2.6%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Dec 10, 2024 1,686 $155,685 140,873 (-1.2%) Payment of Exercise Price
    Chief Financial Officer
    Officer
    Nov 29, 2024 43,340 $3,150,818 321,604 (+13.5%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 33,660 $2,314,125 217,379 (+15.5%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 120,715 $11,198,151 266,849 (-45.2%) Sale
    Chief Financial Officer
    Officer
    Nov 29, 2024 18,630 $1,374,335 157,549 (+11.8%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 60,885 $4,378,240 278,264 (+21.9%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 127,930 $11,867,119 138,919 (-92.1%) Sale
    Chief Financial Officer
    Officer
    Nov 29, 2024 65,960 $4,795,292 387,564 (+17.0%) Exercise/Conversion
    Chief Financial Officer
    Officer
    Nov 29, 2024 26,170 $1,515,766 183,719 (+14.2%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Nov 27, 2024 88,119 $8,106,948 99,599 (-88.5%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 10,399 $956,708 80,801 (-12.9%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 57,294 $5,259,297 187,718 (-30.5%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 88,119 $5,761,220 245,012 (+36.0%) Exercise/Conversion
    Chief Medical Officer
    Officer
    Nov 27, 2024 5,200 $477,381 94,399 (-5.5%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 3,199 $293,679 91,200 (-3.5%) Sale
    Chief Medical Officer
    Officer
    Nov 27, 2024 57,294 $3,318,468 156,893 (+36.5%) Exercise/Conversion
    Director
    Nov 26, 2024 5,879 $359,618 11,587 (+50.7%) Exercise/Conversion
    Director
    Nov 26, 2024 6,788 $620,356 8,920 (-76.1%) Sale
    Director
    Nov 26, 2024 4,121 $252,823 15,708 (+26.2%) Exercise/Conversion
    Chief Commercial Officer
    Officer
    Nov 6, 2024 5,000 $456,400 73,127 (-6.8%) Sale
    Chief Medical Officer
    Officer
    Nov 6, 2024 20,590 $1,883,985 104,599 (-19.7%) Sale
    Chief Medical Officer
    Officer
    Nov 6, 2024 5,000 $457,500 99,599 (-5.0%) Sale
    Chief Medical Officer
    Officer
    Nov 6, 2024 25,000 $1,448,000 125,189 (+20.0%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Oct 25, 2024 514 $0 21,221 (+2.4%) Exercise/Conversion
    Evp, Corporate Affairs Gc
    Officer
    Oct 25, 2024 242 $21,538 20,979 (-1.2%) Payment of Exercise Price